There are 3161 resources available
793TiP - A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005
Presenter: Domenica Lorusso
Session: Poster session 02
795TiP - A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors
Presenter: Isabelle Ray-Coquard
Session: Poster session 02
796TiP - Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS)
Presenter: Junhwan Kim
Session: Poster session 02
797TiP - Tislelizumab combined with chemotherapy as neoadjuvant treatment for advanced endometrial cancer: A prospective, single-arm, open-label clinical study
Presenter: Zheng Hu
Session: Poster session 02
798TiP - Stereotactic radiotherapy alone or followed by niraparib for oligometastases or oligoprogression in ovarian cancer following PARP inhibitor therapy: SOPRANO trial
Presenter: Susana Banerjee
Session: Poster session 02
856P - Safety of neoadjuvant PARP inhibitor and immunotherapy in locally advanced HPV-negative head and neck squamous cell carcinoma (PRIME H&N Study)
Presenter: Luigi Lorini
Session: Poster session 02
857P - Safety and efficacy of neoadjuvant immunochemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial
Presenter: Jing Yan
Session: Poster session 02
Resources:
Abstract
858P - Preoperative neoadjuvant chemoimmunotherapy for locally advanced head and neck squamous cell carcinoma patients: A prospective, single-arm, phase II clinical study
Presenter: Ping Han
Session: Poster session 02